References
- Peng L, Xiao K, Ottaviani S, et al. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;1–7. DOI:https://doi.org/10.1080/14740338.2020.1799975.
- Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.
- Hoffman KB, Demakas AR, Dimbil M, et al. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014;37(11):971–980.
- Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252.
- Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697.
- Ottaviani S, Stebbing J. What is the best drug to treat COVID-19? The need for randomized controlled trials. Preprints. 2020. DOI:https://doi.org/10.1016/j.medj.2020.04.002.